MYGN: Q2 revenue declined 11% year-over-year, prompting lower 2026 guidance and operational changes
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue fell 11% year-over-year to $190.7 million, driven by lower prenatal volumes and payer reimbursement friction, despite strong hereditary cancer and mental health test growth. Guidance for 2026 revenue and gross margin was lowered, and operational initiatives are underway to address reimbursement and efficiency challenges.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue fell 11% year-over-year to $190.7 million, driven by lower prenatal volumes and payer reimbursement friction, despite strong hereditary cancer and mental health test growth. Guidance for 2026 revenue and gross margin was lowered, and operational initiatives are underway to address reimbursement and efficiency challenges.
Based on